393 related articles for article (PubMed ID: 27348433)
1. The Role of Anti-VEGF Therapy in the Treatment of Diabetic Macular Edema.
Moshfeghi DM; Kaiser PK; Michels S; Midena E; Kitchens JW; Prenner JL; Regillo CD; Reichel E
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6 Suppl):S4-S14. PubMed ID: 27348433
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
4. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
Ashraf M; Souka AA; ElKayal H
Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
[TBL] [Abstract][Full Text] [Related]
5. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
Hussain RM; Ciulla TA
Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
[TBL] [Abstract][Full Text] [Related]
6. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
7. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
8. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
Krick TW; Bressler NM
Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
[TBL] [Abstract][Full Text] [Related]
9. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.
Wood EH; Karth PA; Moshfeghi DM; Leng T
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235
[TBL] [Abstract][Full Text] [Related]
10. Diabetic macular edema.
Lang GE
Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
[TBL] [Abstract][Full Text] [Related]
11. Frequency of Bevacizumab and Ranibizumab Injections for Diabetic Macular Edema in Medicare Beneficiaries.
Wu CM; Wu AM; Greenberg PB; Yu F; Lum F; Coleman AL
Ophthalmic Surg Lasers Imaging Retina; 2018 Apr; 49(4):241-244. PubMed ID: 29664980
[TBL] [Abstract][Full Text] [Related]
12. Switching Anti-VEGF Drugs in the Treatment of Diabetic Macular Edema.
Banaee T; Ashraf M; Conti FF; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2017 Sep; 48(9):748-754. PubMed ID: 28902336
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.
Ehlers JP; Yeh S; Maguire MG; Smith JR; Mruthyunjaya P; Jain N; Kim LA; Weng CY; Flaxel CJ; Schoenberger SD; Kim SJ
Ophthalmology; 2022 Jan; 129(1):88-99. PubMed ID: 34446301
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
15. Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients.
Ruiz-Moreno JM; de Andrés-Nogales F; Oyagüez I
BMC Ophthalmol; 2020 Sep; 20(1):371. PubMed ID: 32943041
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept for the treatment of diabetic macular edema.
Harkins KA; Haschke M; Do DV
Immunotherapy; 2016 May; 8(5):503-10. PubMed ID: 26907516
[TBL] [Abstract][Full Text] [Related]
17. Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey.
Yilmaz M; Citirik M; Rahmanlar H; Alkan A; Gursoz H
Rom J Ophthalmol; 2022; 66(4):304-309. PubMed ID: 36589330
[No Abstract] [Full Text] [Related]
18. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
[TBL] [Abstract][Full Text] [Related]
19. Updates on the Clinical Trials in Diabetic Macular Edema.
Demirel S; Argo C; Agarwal A; Parriott J; Sepah YJ; Do DV; Nguyen QD
Middle East Afr J Ophthalmol; 2016; 23(1):3-12. PubMed ID: 26957834
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF therapy for diabetic macular edema.
Stewart MW
Curr Diab Rep; 2014 Aug; 14(8):510. PubMed ID: 24919750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
